OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) and Genentech, Inc., a wholly owned member of the Roche Group (RHHBY), had a disappointment from the FDA. The FDA’s Oncologic Drugs Advisory Committee voted 12 to 1 recommending against the approval of the daily pill Tarceva® as a first-line maintenance use in people with [...]
I realize that I have been blogging about adverse events for the past couple of day but, let’s face it; the pharmaceutical industry lives or dies by the number of adverse events (AEs) that are reported for approved and marketed drugs. In any event, I came upon [...]
This weekend we ran screens of several drug and biotech companies in our quest for ‘cheap stocks’ in the BioHealth sector. The intent is not solely for buyout targets because we prefer to look at value stocks rather than just picking buyout hopefuls. The obvious issue that makes most of [...]
.jpg)
I suspect that many of you (after reading the title of this post) might be expecting another rant about the need for new antibiotics to treat infections caused by multiple drug resistant strains of bacteria. Sorry to disappoint you because that isn’t what this post [...]
Genzyme Corp. (Nasdaq: GENZ) issued a press release defending itself after such a large stock drop today due to the FDA notice on foreign particles being present in some drugs.
The company announced that it has issued letters to U.S. healthcare providers regarding its enzyme replacement products Cerezyme® (imiglucerase for injection), [...]
